Genetic Medicines to Treat Cardiovascular Disease

Jan 25–28, 2027 | Keystone Resort, Keystone, CO, United States
Scientific Organizers: Rick Dewey, Litsa G. Kranias, and James S. Ware

  In Person
  On Demand
×

-

Jan 25–28, 2027 | Keystone Resort, Keystone, CO, United States

Scientific Organizers: Rick Dewey, Litsa G. Kranias, and James S. Ware

Supported by the  Directors' Fund

***Meeting program subject to change.

Available Formats:   = In Person     = On Demand
Monday, January 25, 2027
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, January 26, 2027
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Sekar Kathiresan †, Verve Therapeutics
The Human Genome as Teacher and Target: Two Decades of Genomic Discovery to Genomic Medicines
New Trailheads: Target Identification for Genetic Medicines in CV Disease
9:00–11:15 AM
James S. Ware, Imperial College London
Large Scale Genomic Discovery of Causal Mechanisms in Heart Failure
Victoria Parikh †, Stanford University School of Medicine
Genotype-Phenotype Correlation in Inherited Cardiovascular Disease
Rick Dewey, Versant Ventures
Target Selection for Genetic Medicines: Biobanks to Human Proof of Concept
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Panel Discussion 1: Development, Regulatory, Safety, and Ethical Considerations (including long-term and off-target effects of genetic medicines)
11:15–12:15 PM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 1: Emerging Biological Insights Driving the Next Generation of Genetics Medicines for CV Disease
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Mechanisms and Models: From Variation to Validation
5:00–7:00 PM
Cassady Rupert †, Propria LLC
Modeling Human Cardiac Biology with Multi-Dimensional Engineered Human Heart Tissues
Christine E. Seidman †, Harvard Medical School
Modeling Cardiovascular Disease: Genetics, Cellular Systems, Human Models
Litsa G. Kranias, University of Cincinnati
PLN Cardiomyopathy: From Bedside to Bench and Back to Bedside
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, January 27, 2027
Breakfast
7:00–8:00 AM
Gene Silencing in Cardiovascular Disease and Promising Avenues
8:00–11:00 AM
Marianna Fontana †, University College London
CRISPR-Cas9 Gene Editing for TTR Amyloid Cardiomyopathy
Kate A Fitzgerald †, University of Massachusetts Medical School
From RNAi Mechanism to Medicine; the Path to a New Class of Genetic Medicines
Euan A. Ashley †, Stanford University
Allele-Specific Silencing in Cardiomyopathy
Jin Billy Li †, Stanford University
Endogenous RNA Editing in CV Disease: Mechanisms and Therapeutic Applications
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Therapeutic Gene Augmentation Strategies in CV Disease
5:00–7:00 PM
Roger J. Hajjar †, Mass General Brigham
Engineering the Failing Heart: Innovations in Cardiac Gene Therapy
Annemieke Aartsma-Rus †, Leiden University Medical Center
Exon Skipping to Restore Gene Expression in Muscle Disease
Speaker to be Announced
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Thursday, January 28, 2027
Breakfast
7:00–8:00 AM
Homing for Cures: Cardiomyocyte-Directed Delivery Approaches
8:00–11:00 AM
Luk H. Vandenberghe †, Harvard Medical School
Engineering Viral Delivery Systems
Speaker to be Announced
James Dahlman †, Georgia Tech / Emory Medical School
Lipid Nanoparticles: Past, Present, and Future of RNA Delivery
William M Flanagan †, Avidity Biosciences, Inc.
Antibody-Oligo Conjugates for Striated Muscle-Enriched Delivery
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Panel Discussion 2: Navigating the Valley of Opportunity: Moving Ideas from Idea to Products for Patients with Academia, Venture Capital, and Pharma
11:00–12:00 PM
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight 2: Emerging Translational Strategies in CV Disease
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Products to Patients: Therapeutic Development and Trial Design
5:00–6:45 PM
Laura F. Michael †, Eli Lilly and Company
Lp(a) - From Genetic Insight to Novel Biology and Breakthrough Therapy
Pushkal Garg †, Alnylam Pharmaceuticals, Inc.
Industry Perspective on Clinical Development of Genetic Therapies
Gene Bukhman †, Brigham and Women's Hospital
Global Health Equity Considerations for New Treatments for CV Disease
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions
6:45–7:00 PM
Social Hour with Dinner
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Friday, January 29, 2027
Departure
12:00–11:59 PM

Subscribe for Updates